

## FINTEC GLOBAL BERHAD

(FORMERLY KNOWN AS ASIA BIOENERGY TECHNOLOGIES BERHAD)
(Company No. 774628-U)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE 1ST QUARTER AND YEAR-TO-DATE ENDED 30 JUNE 2018

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

# CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE 1ST QUARTER AND YEAR-TO-DATE ENDED 30 JUNE 2018

(The figures have not been audited)

	(The ligures ha	ve not been audi	ieu)			
		Quarter Ende			r-To-Date End	_
	30.06.2018	30.06.2017	Changes	30.06.2018	30.06.2017	Changes
	RM'000	RM'000	%	RM'000	RM'000	%
Revenue	437	1,909	(77.1)	437	1,909	(77.1)
Cost of sales	(86)	(2,260)	96.2	(86)	(2,260)	96.2
Gross profit/(loss)	351	(351)	200.0	351	(351)	200.0
Other operating income	372	307	21.2	372	307	21.2
Operating expenses	(1,248)	(4,272)	70.8	(1,248)	(4,272)	70.8
Fair value (loss)/gain on investment securities	(30,978)	43,490	(171.2)	(30,978)	43,490	(171.2)
Finance costs	(62)	(101)	38.6	(62)	(101)	38.6
(Loss)/Profit before taxation	(31,565)	39,073	(180.8)	(31,565)	39,073	(180.8)
Tax expense	-	-	-	-	-	-
(Loss)/Profit for the period	(31,565)	39,073	(180.8)	(31,565)	39,073	(180.8)
Other comprehensive loss:  Items that may be subsequently reclassified to profit or loss:						
Foreign currency translation differences for foreign operations	(1)	-	_	(1)	-	_
Total comprehensive (loss)/income for the period	(31,566)	39,073	(180.8)	(31,566)	39,073	(180.8)
(Loss)/Profit attributable to: Owners of the Company Non-controlling interest	(31,561) (4)	39,088 (15)	(180.7) 73.3	(31,561) (4)	39,088 (15)	(180.7) 73.3
	(31,565)	39,073	(180.8)	(31,565)	39,073	(180.8)
Total comprehensive (loss)/income attributable to: Owners of the Company	(31,562)	39,088	(180.7)	(31,562)	39,088	(180.7)
Non-controlling interest	(4)	(15)	73.3	(4)	(15)	73.3
	(31,566)	39,073	(180.8)	(31,566)	39,073	(180.8)
			Quarte	r Ended	Year-To-Da	ate Ended
			30.06.2018	30.06.2017	30.06.2018	30.06.2017
			Sen per	Sen per	Sen per	Sen per
			share	share	share	share
						(Audited)
Earnings/(Loss) Per Share attributable to equity owners of the Company (sen)	<i>'</i>					
- Basic			(5.53)	10.09	(5.53)	10.09
- Diluted			N/A	7.53	N/A	7.53

## Notes:

The condensed consolidated statements of comprehensive income are prepared based on the consolidated results of the Group for the quarter ended 30 June 2018 and is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2018

(The figures have not been audited)		
	Unaudited As at 30.06.2018 RM'000	Audited As at 31.03.2018 RM'000
ASSETS		
Non-current assets	0.004	0.454
Property, plant and equipment	3,061	3,154
Investment securities	96,246	124,469
	99,307	127,623
Current assets		
Receivables, deposits and prepayments	14,518	11,030
Investment securities	8,285	235
Deposit with Financial Institution	54,401	60,568
Inventories	319	321
Cash and cash equivalents	1,161	2,537
	78,684	74,691
TOTAL ASSETS	177,991	202,314
EQUITY AND LIABILITIES		
Share capital	92,421	81,873
ICPS	46,258	53,228
Reserves	11,458	11,459
Retained profits	7,249	38,810
Total equity attributable to owners of the Company	157,386	185,370
Non-controlling interest	(1,640)	(1,636)
Total equity	155,746	183,734
Current liabilities		
Payables and accruals	22,239	18,574
Borrowing	-	-
Current tax liabilities	6	6
Total current liabilities	22,245	18,580
Total liabilities	22,245	18,580
TOTAL EQUITY AND LIABILITIES	177,991	202,314
Net assets per share attributable to equity holders of the Company (sen)	26.60	35.25

The condensed consolidated statement of financial position is prepared based on the consolidated results of the Group for the quarter ended 30 June 2018 and is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

Notes:

Net assets per share is arrived at based on the total Group's net assets over the 591,742,772 ordinary shares in issue as at 30 June 2018.

(Formerly known as Asia Bioenergy Technologies Berhad)
(Company No. 774628-U)
(Incorporated in Malaysia)

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR-TO-DATE ENDED 30 JUNE 2018

(The figures have not been audited) ---- Attributable to Owners of the Company ----------- Non-distributable -----> Distributable **Exchange** (Accumulated Non-Total Share Share **Warrant Translation** losses)/ controlling Capital ICPS Premium Reserve Retained profits Reserve Total Interest Equity RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 Audited Balance as at 1 April 2017 56,005 1,298 334 (4,629)53,008 (1,562)51,446 43.439 43.365 Total comprehensive profit for the period 43.439 (74)Transaction with owners of the Company: Issuance of ICPS with free warrants 61,367 10,575 71,942 71,942 Issuance of ordinary shares pursuant to conversion of ICPS 12.073 (8.139)3.934 3,934 Issuance of ordinary shares pursuant to SIS 13,782 13,782 13,782 Issuance of ordinary shares pursuant to exrcise of Warrant B 8 8 13 (5)(743)(743)Share issuance expenses (743)Total transctions with owners of the Company 25,868 53,228 (743)10,570 88,923 88,923 10,904 81,873 53,228 555 38,810 185,370 (1.636)183,734 Balance as at 31 March 2018 Unaudited Balance as at 1 April 2018 81,873 53,228 555 10,904 38,810 185,370 (1,636)183,734 Loss for the period (31,561)(31,561)(4) (31,565)Other comprehensive loss (1) (1) (1) Total comprehensive loss for the period (1) (31,562)(4) (31,566)(31,561)Transaction with owners of the Company: Issuance of ordinary shares pursuant to conversion of ICPS 10,548 (6,970)3,578 3,578

#### Notes:

Balance as at 30 June 2018

The condensed consolidated statement of changes in equity is prepared based on the consolidated results of the Group for the quarter ended 30 June 2018 and is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

555

10,904

(1)

7,249

157,386

(1,640)

155,746

46,258

92,421

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

# CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEAR-TO-DATE ENDED 30 JUNE 2018

(The figures have not been audited)

	Year-To-Date Ended	
•	30.06.2018	30.06.2017
CASH FLOWS FROM OPERATING ACTIVITIES	RM'000	RM'000
(Loss)/Profit before tax	(31,565)	39,073
Adjustments for :	(- ,,	,-
Depreciation of property, plant and equipment	94	259
Interest income	(437)	-
Gain on disposal of investment	-	(40)
Share-based payment reserve	-	1,263
Loss on disposal of investment securities	35	119
Fair value loss/(gain) on investment securities	30,978	(43,490)
Gain on unrealised foreign exchange	(372)	(266)
Interest expense	62	101
Operating loss before working capital changes	(1,205)	(2,981)
Changes in working capital:		4.000
Proceeds from disposal of Investment securities  Purchase of investment securities	- (10,840)	1,909 (5,896)
Decrease in inventories	(10,640)	(5,690)
(Increase)/decreased in trade and other receivables	(3,450)	1,046
Increase in trade and other payables	3,564	947
Cash used in operations	(11,929)	(4,975)
Income tax paid	(38)	(4.075)
Net cash used in operating activities	(11,967)	(4,975)
CASH FLOWS FROM INVESTING ACTIVITIES		
Proceeds from disposal of investment	-	40
Interest received	437	-
Net cash generated from investing activities	437	40
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of shares pursuant to SIS	-	6,715
Proceeds from issuance of shares pursuant to conversion	0.570	
of ICPS (Repayment of borrowing)/Borrowing	3,578	- 3,634
Interest paid	(62)	(101)
Net cash generated from financing activities	3,516	10,248
Net (decrease)/ increase in cash and cash equivalents	(8,014)	5,313
Effect of exchange rate changes	471	-
Cash and cash equivalents at beginning of the year	63,105	194
Cash and cash equivalents at end of the period	55,562	5,507
Cash and cash equivalents consist of:		
Deposits with lincensed financial instituition	54,401	-
Cash and bank balances	1,161	5,507
	55,562	5,507

## Notes:

The condensed consolidated statements of cash flow for the quarter ended 30 June 2018 is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

#### A1 Basis of preparation

The interim financial statements are unaudited and have been prepared in accordance with Malaysia Financial Reporting Standards ("MFRSs") 134: Interim Financial Reporting, International Financial Reporting Standards ("IFRSs") 134: Interim Financial Reporting and paragraph 9.22 of the ACE Market Listing Requirements ("AMLR") of Bursa Malaysia Securities Berhad ("Bursa Securities").

The interim financial statements should be read in conjunction with the Group's audited consolidated financial statements for the financial year ended 31 March 2018. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 March 2018.

The accounting policies and methods of computation adopted by the Group in this interim financial statements is consistent with those adopted in the audited financial statements for the financial year ended 31 March 2018 except for the adoption of the following MFRSs and amendments to MFRSs which came into effect for annual periods beginning on or after 1 January 2018 and are applicable for the Group's interim financial statements for the quarter and year-to-date ended 30 June 2018, as disclosed below:

## MFRSs, Amendments to MFRSs and IC Interpretation

MFRS 9 Financial Instruments

MFRS 15 Revenue from Contracts with Customers

MFRS 15 Clarifications to MFRS 15

Amendments to MFRS 2 Classification and Measurement of Share-based Payment Transactions

Amendments to MFRS 140 Transfer of Investment Property

IC Interpretation 22 Foreign Currency Transactions and Advance Consideration

Annual Improvements to MFRS Standards 2014 - 2016 Cycles:

- Amentmends to MFRS 1 Deletion of Short-term Exemptions for First-time Adopters
- Amentmends to MFRS 128 Measuring an Associate or Joint Venture at Fair Value

The adoption of the above standards and interpretation are not expected to have a material impact on the financial statements in the period of application except as discussed below:

#### **MFRS 9 Financial Instruments**

MFRS 9 introduces new requirements for classification and measurement of financial assets, impairment of assets and hedge accounting. Financial assets are classified according to their contractual cash flow characteristics and the business model under which they are held. The impairment requirements in MFRS 9 are based on expected credit loss model and replace the MFRS 139 Financial Instruments: Recognition and Measurement incurred loss model.

MFRS 9 if effective for annual periods beginning on or after 1 January 2018, with early application permitted. Retrospective application is required, but comparative information is not compulsory. The Group applied the new standard without restating comparative information and recognises any difference between the previous carrying amount and the carrying amount at the beginning of the annual reporting period at the date of initial application in the opening retained earnings. Based on the preliminary assessment of the adoption of MFRS 9, the Group concluded that the new standard did not have a significant impact to the interim financial statements.

The Group applied the simplified approach and assesed the lifetime expected losses on trade receivable, which did not have a material impact on the impairment allowance.

## MFRS 15 Revenue from Contracts with Customers

MFRS 15 establishes a single comprehensive model for revenue recognition. Under MFRS 15, revenue is recognised at an amount that reflects the consideration which an entity expects to be entitled in exchange for transferring goods or services to a customer.

The new standard will supersede all current revenue recognition requirements under MFRS. Either a full retrospective application or a modified retrospective application is required for annual periods beginning on or after 1 January 2018.

MFRS 15 provides a single model for accounting for revenue arising from contracts with customers, focusing on the identification and satisfaction of performance obligations, i.e. when 'control' of the distinct promised goods or services underlying the particular performance obligation is transferred to the customers.

The adoption of this new MFRS 15 did not have a significant impact on the results and financial position of the Group.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

## Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

#### A2 Auditors' report on preceding annual financial statements

There were no audit qualifications in relation to the audited consolidated financial statements of the Group for the financial year ended 31 March 2018.

## A3 Seasonal or cyclical factors

There were no significant seasonal or cyclical factors that will materially affect the business of the Group in current period. However, the Group's results are largely influenced by, amongst others, the market prices of quoted investments as well as the timing of disposal of investments by the Group.

## A4 Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial guarter and financial year-to-date ended 30 June 2018.

## A5 Material changes in estimates

There were no changes in estimates that have a material effect in the current financial quarter and financial year-to-date results.

#### A6 Debt and equity securities

Save as disclosed in the following, there were no issuance, cancellations, repurchases, resale and repayment of debt and equity securities, share buy backs, share cancellation, shares held as treasury share and resale of treasury shares during the current financial quarter and financial year-to-date ended 30 June 2018.

a) During the financial year to date, the Company issued new ordinary shares pursuant to the conversion of ICPS are as below:

Quarter and
Year-To-Date Ended
30.06.2018

No. of shares RM'000

Conversion of ICPS 65,928 10,548

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

## A7 Dividend paid

There were no dividends paid by the Group during the financial quarter ended 30 June 2018.

#### A8 Segmental information

Segment information based on the Group's activities is set out below. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

#### **Cumulative Quarter Ended 30 June 2018**

	Incubation RM'000	Portfolio Investment RM'000	Green Technology products RM'000	O & G services RM'000	Elimination RM'000	Group RM'000
Revenue						
External sales	437	-	-	-		437
Intersegment	437	-	-	-	-	437
Results from operating activities	-	(30,749)	(53)	(68)		(30,870)
Finance costs		(62)				(62)
Share of profit of associates						-
Net unallocated expenses						(633)
Profit before taxation					_	(31,565)
Tax expense						-
Profit for the period						(31,565)
Segment assets Unallocated assets	57,236	115,347	1,325	3,777		177,685 306
Total assets					_	177,991
Segment liabilities Unallocated liabilities	8,530	7,663	246	5,800		22,239 6
Total liabilities					<u> </u>	22,245

## A9 Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment during the current financial quarter and year-to-date ended 30 June 2018.

## A10 Material events subsequent to the end of the quarter

Save as disclosed in Note B11, there were no material events occurring subsequent to the end of the current quarter.

## A11 Changes in the composition of the Group

Save as disclosed in Note B11, there were no changes in the composition of the Group during the current quarter and year-to-date ended 30 June 2018.

## **A12 Contingent liabilities**

The Company provides corporate guarantees amounting to RM3.385 million (as at 31 March 2017: RM NIL) in lieu of security deposits required by suppliers for leasing of scaffolding equipment to a wholly owned subsidiary. Consequently, the Company is contingently liable for the amounts of corporate guarantees fully utilised by the wholly owned subsidiary.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

# Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

## **A13 Capital commitments**

As at 30 June 2018, the Group has no material capital commitments.

## A14 Related party transactions

During the financial quarter ended 30 June 2018, the Directors are of the opinion that the Group has no related party transactions which would have a significant impact on the financial position and business of the Group.

## A15 Additional Disclosure Requirements to the Statements of Comprehensive Income

	Quarter and	
	Year-To-Date Ended	
	30.06.2018	30.06.2017
	RM'000	RM'000
Interest income	437	-
Interest expense	(62)	(101)
Depreciation and amortisation	(94)	(259)
Gain of disposal of quoted or unquoted investments		
or properties (non revenue)	-	40
Fair value (loss)/gain on marketable securities	(30,978)	43,490
Unrealised Foreign exchange gain	372	266
Exceptional items	-	-

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

#### **B1** Performance review

Current Year-to-date vs. Previous Year-to-date

		Year-To-Date	e Ended		
	30.06.2018	30.06.2017	Change	s	
Key Profit or Loss items:	RM'000	RM'000	RM'000	%	
Revenue	437	1,909	(1,472)	(77.1)	
(Loss)/Profit Before Tax	(31,565)	39,073	(70,638)	(180.8)	
Net (loss)/pofit attributable to equity holders	(31,561)	39,088	(70,649)	(180.7)	
	Year-To-Date Ended				
	30.06.2018	30.06.2017	Change	s	
Key Balance Sheet Items:	RM'000	RM'000	RM'000	%	
Investment securities :-					
Non-current	96,246	92,060	4,186	4.5	
Current	8,285	1,624	6,661	410.2	
	104,531	93,684	10,847	11.6	
Trade and other payables	22,239	2,281	19,958	875.0	

The Group's revenue for the current quarter and year-to-date ending 30 June 2018 was RM0.437 million, a decrease of RM1.472 million or -77.1% as compared to RM1.909 million in the previous year's corresponding period. The revenue generated for the quarter was interest income received from the fixed deposits placed with financial institutions. During the current quarter, there were no quoted securities traded.

The Group made a loss before tax of RM31.565 million for the year-to-date as opposed to profit before tax of RM39.073 million in the corresponding period ending 30 June 2017 and the net loss attributable to equity holders was RM31.561 million, an increase of loss of RM70.649 million or -1.8x as compared to the net profit attributable to equity holders of RM39.088 million in previous year's corresponding period.

The increase of losses is mainly due to the fair value loss on quoted securities of RM30.978 million arising from the general reduction in market prices of such quoted securities. The poor performance of these quoted securities was in line with the poor market sentiments and lack lustre performance of our local bourse and the regional markets.

The Group's Investment in marketable securities grew by RM10.847 million or 11.6% to RM104.531 million as at 30 June 2018 as compared to RM93.684 million as at 30 June 2017, which was mainly driven by an increase in total investment at a cost of approximately RM13.752 million and a decrease in value of investments by approximately RM19.153 million.

Total Trade and other payables increased by 8.8x or RM19.958 million over the same period to RM22.239 million as at 30 June 2018, which was mainly due to the following:-

- (a) increased of trade payables for medium to long term portfolio investments of approximately RM7.579 million and payables in relation to the scaffolding project under the Oil & Gas division of approximately RM3.844 million.
- (b) deposits received of RM8.413 million as Proof of Fund Deposits pertaining to a proposed joint bidding for a student housing project by Asiabio Builders Sdn. Bhd., a wholly owned subsidiary of the Group.

Performance of the respective operating business segments for the year-to-date ending 30 June 2018 as compared to the previous corresponding period is analysed as follows:-

	Year-To-Date Ended				
	30.06.2018	30.06.2017	Change	s	
(Loss)/Profit Before Tax by Segments	RM'000	RM'000	RM'000	%	
Portfolio investment	(30,811)	43,134	(73,945)	(171.4)	
Green technology products	(53)	(166)	113	68.1	
O & G services	(68)	(2,012)	1,944	96.6	

## Portfolio investment

Loss before tax increased by RM73.945 million (-1.7x) to RM30.811 million was mainly due to the reduction in market prices of the Group's strategic investments in Malaysia which was affected by the poor local market performance and lack lustre regional bourses.

## Green technology products

Loss before tax reduced by RM0.113 million (68.1%) to RM0.053 million mainly due to a decrease in depreciation for plant and machineries.

## O & G services

Loss before tax reduced by RM1.944 million (96.6%) to RM0.068 million mainly due to a decrease in administration and general overhead during the current quarter.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

#### B2 Variation of results against immediate preceding quarter

	Current	Preceding	
	quarter	quarter	
	30.06 2018	31.03.2018	Changes
	RM'000	RM'000	%
Revenue	437	9,759	(95.5)
Loss before taxation	(31,565)	(36,799)	14.2

The Group registered revenues of RM0.437 million for the current quarter ending 30 June 2018, a decrease of RM9.322 million or 95.5% as compared to RM9.759 million for the immediate preceding quarter ending 31 March 2018. The decrease in revenue was mainly due to no quoted securities traded during the current period.

Loss before taxation incurred by the Group for the 1st quarter ending 30 June 2018 was RM31.565 million, a reduction of RM5.234 million or 14.2% as compared to a loss before tax of RM36.799 million in the preceding quarter. The reduction in loss before tax was mainly due to impairment losses on trade receivables accounted for in the preceding quarter.

## **B3** Prospects

As the Group's performance is principally driven by its investments in marketable securities which is represented by it's listed incubatees, the Group's results will always be subjected to unpredictable market forces. Management is however cautiously optimistic that the performance of its incubatees in the medium term will improve once the market stabilizes. In the interim, management is actively examining several potential investments and incubation projects and will be making the relevant disclosures in due course.

## B4 Profit forecast, profit guarantee and internal targets

The Group did not provide any profit forecast, profit guarantee or made public any internal targets for the period under review.

#### B5 Income tax expense

During the financial quarter ended 30 June 2017, no provision for taxation needed to be provided as the Group had adequate unabsorbed tax losses brought forward from previous years to offset the profit incurred, if any, in the current financial quarter.

## **B6** Trade Receivables

	As a	As at	
	30.06.2018	30.06.2017	
	RM'000	RM'000	
Trade receivables	46	1,545	

The ageing analysis of the Group's trade receivables to non-related parties as at 30 June 2018 is as follows:

	As	at
	30.06.2018 RM'000	30.06.2017 RM'000
Neither past due nor impaired Past due not impaired:	20	1,394
91 - 180 days	-	32
> 181 days	26	119
Impaired	-	-
	46	1,545

## B7 Group's borrowings and debt securities

The Group has no borrowing or debt securities as at end of the reporting date.

## **B8** Material litigation

As at this reporting date, neither the Company nor its subsidiary companies are engaged in any litigation or arbitration, either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiary companies and the Board is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings, which might materially and adversely affect the position or business of the Company or its subsidiary companies.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

#### B9 Dividends

There were no dividends declared for the financial quarter ended 30 June 2018.

## B10 Earnings per share ("EPS")

## a) Basic EPS

	Quarter and Year-To-Date Ended	
	30.06.2018	30.06.2017
Profit/(Loss) attributable to the owners of the Company (RM'000)	(31,561)	39,088
Weighted average number of ordinary shares in issue ('000)	570,679	387,558
Basic EPS (sen)	(5.53)	10.09
b) Diluted EPS	Quartan	. a.u.d
	Quarter Year-To-Da	
	30.06.2018	30.06.2017
Profit/(Loss) attributable to the owners of the Company (RM'000)	(31,561)	39,088
Weighted average number of ordinary shares in issue ('000) Effective of dilution from conversion of ICPS ('000)	570,679 710,412	387,558
Effective of dilution from detachable warrants A ('000)  Effective of dilution from detachable warrants B ('000)	131,296 89,883	131,296
Adjusted weighted average number of ordinary shares in issue and issuable ('000)	1,502,270	518,854
Diluted EPS (sen)	N/A	7.53

The diluted EPS is computed based on the profit attributable to the owners of the Company divided by the weighted average number of ordinary shares in issue during the financial period and assume the full conversion of the ICPS and warrants into ordinary shares.

## **B11 Status of corporate proposals**

a) On 13 July 2018, the Company's wholly-owned subsidiary, Fintec Global (HK) Limited (Company No. 2679962) ("FG"), had on 11 July 2018 acquired a total of 100,000 ordinary shares representing 100% of the share capital of E99 Limited (Company No. 2662278) ("E99") for a total cash consideration of HKD100,000.00, equivalent to RM51,344.10 only. Consequent to the Acquisition of Shares, E99 shall become a wholly-owned subsidiary of FG, which in turn is a wholly-owned subsidiary of FINTEC.

Timoframo

## **B12 Status of Utilisation of Proceeds**

Status of utilisation of proceeds as at 30 June 2018.

	ation utilisation of W'000 proceeds
Rights issue of ICPS with warrants	
i) Investment in quoted securities - Focus 10,489 - 10,489 ICPS	- Within 12 months
ii) Investment in quoted securities - Vsolar 8,200 - 8,200 Rights Shares	- Within 12 months
iii) Working capital 5,000 (2,217) 2,783	204 Within 24 months
iv) Investment in unquoted incubatees and/or 47,410 (1,071) 46,339 start-up companies to be identified	- Within 36 months
v) Estimated expenses 844 (640) 204	(204) immediate
71,943 (3,928) 68,015	<u> </u>

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

## B13 Non-cash items to the Condensed Consolidated Statement of Comprehensive Income

	Quartei	Quarter and	
	Year-To-Date Ended		
	30.06.2018 RM'000	30.06.2017 RM'000	
Total Comprehensive (Loss)/Profit	(31,565)	39,073	
Non-Cash items:			
Depreciation of property, plant and equipment	(94)	(259)	
Gain on unrealised foreign exchange	372	266	
Gain/(Loss) on change in fairvalue	(30,978)	43,490	
Share-based payment reserve	-	(1,263)	
	(30,700)	42,234	
Total Comprehensive loss before non-cash items	(865)	(3,161)	

## **B14** Authorisation for issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with the resolution of the Board of Directors.

On Behalf of the Board

Leung Kok Keong Lim Lee Kuan Ng Sally Company Secretaries